Compare ALKS & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKS | BIO |
|---|---|---|
| Founded | 1987 | 1952 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 10.1B |
| IPO Year | 2012 | 1994 |
| Metric | ALKS | BIO |
|---|---|---|
| Price | $40.15 | $377.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 4 |
| Target Price | $43.43 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 1.7M | 242.2K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ N/A | N/A |
| Revenue | $1,475,899,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | $24.26 | $2.74 |
| Revenue Next Year | $4.47 | $3.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.65 |
| 52 Week Low | $27.00 | $236.73 |
| 52 Week High | $55.67 | $396.23 |
| Indicator | ALKS | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 25.56 | 54.04 |
| Support Level | $36.25 | $364.41 |
| Resistance Level | $51.25 | $396.23 |
| Average True Range (ATR) | 1.45 | 9.46 |
| MACD | -0.46 | -1.49 |
| Stochastic Oscillator | 7.68 | 55.13 |
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.